A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis
← catalyst calendarNCT07570862 · readout in 1,046 d
Sponsored by Fate Therapeutics (industry) · FATE — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
53estimated
Sites
6
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-27 | actual | When the study began enrolling |
| Primary completion | 2029-07-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-01-31 | estimated | The whole study's end, after follow-up |
| First posted | 2026-05-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Lupus Nephritis
- Systemic Lupus Erythematosus
- SLE - Systemic Lupus Erythematosus
- Lupus Nephritis - WHO Class III
- Lupus Nephritis - WHO Class IV
Intervention
- Biological: FT819
Primary outcome
what the primary-completion date above is the date OFComplete Renal Response (CRR) at Week 26
measured Week 26
Permalink · FATE's whole pipeline · Catalyst calendar · Every registered study · What changed